AR and prostate carcinoma: Given the limited mapping studies in prostate cancer, our aim was to develop mapping algorithms to convert scores from disease-specific questionnaires to EQ-5D utility values for patients receiving novel androgen receptor signaling inhibitors (ARSIs).